Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2004-05-28
2009-08-18
Kim, Jennifer Myong M (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S250000, C514S649000
Reexamination Certificate
active
07576073
ABSTRACT:
The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination of a therapeutically effective amount of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor, such as levodopa. The present invention also concerns to the use of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine precursor to manufacture a medicament for treating a neurodegenerative diseases.
REFERENCES:
patent: 3838008 (1974-09-01), Bamberg
patent: 4774244 (1988-09-01), Curtius et al.
patent: 4812447 (1989-03-01), Roberts
patent: 4826875 (1989-05-01), Chiesi
patent: 5047927 (1991-09-01), Sowell et al.
patent: 5556847 (1996-09-01), Johnson et al.
patent: 5763492 (1998-06-01), Johnson et al.
patent: 6696600 (2004-02-01), Frenkel et al.
patent: 2002/0182196 (2002-12-01), McCleary
patent: 1310258 (2003-05-01), None
patent: WO 97/06786 (1997-02-01), None
patent: WO 99/43329 (1999-09-01), None
patent: WO 01/55692 (2001-08-01), None
patent: WO 02/36128 (2002-05-01), None
patent: WO 02/056892 (2002-07-01), None
patent: WO 03/039555 (2003-05-01), None
patent: WO 03/051348 (2003-06-01), None
Wolkowitz et al. Dehydroepiandrosterone (DHEA) treatment of depression. Society of Biological Psychiatry, 1997; 41, pp. 311-318.
Stryjer et al. Amantadien as augmentation therapy in the management of treatment-resistant depression. International Clinical Psychopharmacology, Mar. 2003, vol. 18. No. 2, p. 93-96, abstract.
Belanger et al. Dehydroepiandrosterone and 17b-estradiol improve locomotor activity in MPTP Monkeys. Society for Neuroscience Abstract Viewer and Itinerary Planner, 2003, vol. 2003, abstract No. 610.10.
M. Cyr et al., (2000),Drugs with Estrogen-like Potency and Brain Activity : Potential Therapeutic Application for the CNS, Curr. Pharm. Des. 6, 1287-312.
M. Kawata, (1995),Roles of Steroid hormones and their receptors in structural organization in the nervous system, Neurosci. Res. 24, 1-46; B.S. McEwen and S.E. Alves, (1999),Endocr. Rev.20, 279-307.
B.B. Sherwin, (1997),Estrogen Effects on cognition in menopausal woman, Neurology 48, S21-6.
J.W. Simpkins et al., (1994),The Potential Role for Estrogen Replacement Therapy in the Treatment of the Cognitive Decline and Neurodegeneration Associated With Alzhimer's Disease, Neurobiol. Aging 15.
M. Baldereschi et al., (2000),Parkinson's disease and pakinsonlsm in a longitudinal study, Neurology 55, 1358-63.
G. F. Wooten et al.,Are men at greater risk for Parkinson's disease than women?, J Neurol Neurosurg Psychiatry 2004; 75: 637-639.
K.E. Lyons et al.,Gender Differences in Parkinson's Disease, (1998). Clin. Neuropharmacol. 21, 118-21.
T. Di Paolo,Modulation of Brain Dopamine Transmission by Sex Steroids, (1994). Rev. Neurosci. 5, 27-41.
I.H. Zwain and S.S.C. Yen,Dehydroepladrosterone: Biosynthesis and Metabolism in the Brain, (1999).Endocrinology140, 880-887.
T. Azuma et al.,Neurosteroids in cerebrospinal fluid in neurologic disorders, (1993). J. Neurol. Sci. 120, 87-92.
M. D'Astous et al., (2003).Ehydroepiandrosterone(DHEA)Such as17β -Estradiol Prevents MPTP- Induced Dopamie Depletion in Mice, Synapse 47, 10-14.
M.D. Majewska et al.,The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAAreceptor(1990). Brain Res. 526, 143-146.
S. Callier et al., 2000,Stereospecific Prevention by 17β-Estradiol of MPTP-Induced Dopamine Depletion in Mice, Synapse 37, 245-251.
M. Cyr et al.,Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease, J. Psychiatry Neurosci 2002, 27(1):12-27.
S. Callier et al.,Neuroprotective Properties of 17β-Estradiol, Progestserone, and Raloxifene in MPTP C57BI/6 Mice, Synapse 41:131-138 (2001).
D. E. Dluzen et al.,Estrogen Alters MPTP-Induced Neurotoxicity in Female Mice : Effects on Striatal Dopamine Concentrations and Release, J. Neurochem., vol. 66, No. 2, 1996, 658-666.
P. J. Blanchet et al.,Short-term effects of high-dose 17[beta]-estradiol in postmenopausal PD patients: A crossover study, Neurology, vol. 53(1), Jul. 13, 1999, 91-95.
B. Gomez-Mancilla et al., Effect of estrogen and progesterone on L-Dopa induced dyskinesia in MPTP-treated monkeys, Neurosci Letters, 135(1992)129-132
P.J. Blanchet et al., Regulation of Dopamine Receptors and Motor Behavior Following Pulsatile and Continuous Dopaminergic Replacement Strategies in the MPTP Primate Model, ADV Neurol. 2001; 86:337-344.
D.C. Montgomery, 1991, Third Edition, Design and Analysis of Experiments, Ed. Whisley and Sons, p. 216.
B.S. McEwen and S.E. Ales,Estrogen Actions in the Central Nervous System(1999) Endocr Rev. 20, 279-307.
Morissette M. et al., 2008, “Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain.”, Journal of Steroid Biochemistry & Molecular Biology, 108: 327-338.
Kim Jennifer Myong M
Ogilvy Renault LLP
Universite Laval
LandOfFree
Combined therapy for the treatment of parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined therapy for the treatment of parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined therapy for the treatment of parkinson's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098046